BioSpace News Archive

MANA Therapeutics, a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, announced the final closing of its Series A financing, bringing the total raised to $42 million.

Yokogawa Electric Corporation announces that it has developed the Single Cellome™ System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) along with partner PharmaMar (MSE: PHM) have announced the commercial availability of ZepzelcaTM (lurbinectedin) after receiving conditional approval by Health Canada in September 2021.

Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, announced a deepening of its neuroscience expertise with key hires in human induced pluripotent stem cell biology, translational neuroscience and clinical development.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its IRAKIMiD degrader, KT-413.

Nemaura Medical, Inc. announces today that Chief Executive Officer Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference, which is being held virtually from December 8 – December 9, 2021.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 180,000 shares of the Company’s common stock to two new employees on the date that each employee commences service with the Company.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that its Advanced Biopharma Solutions laboratory, located in Marlborough, Massachusetts, has received its Certificate of Registration from the Clinical Laboratory Improvement Amendments program, following the receipt of a Massachusetts Department of Public Health clinical laboratory license.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced the completion of a positive safety review and enrollment of the last cohort of subjects at the highest dose level in the Company’s second study of its Trypsin Activated Abuse Protected (TAAP) Opioid, PF614.

GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study.